Annalee Armstrong

Just one-third of patients prescribed new medicines filled them within 30 days, with a new report from the Institute for Clinical and Economic Review and West Health suggesting that cost is the problem.

The approval of Hibsago has created a new market for a handful of biopharmas, including Gilead, Arrowhead, and Vir, to fill in.

Gilead Sciences has picked up a new inflammatory disease program from China's PepStar Therapeutics to pair with the Phase 2 inflammatory bowel disease asset emvistegrast.

After sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, analysts are more keen on the personalized mRNA cancer vaccine data that last week spurred a stock selloff for both partners.

The corporate investor arms of Eli Lilly, Sanofi and Pfizer have participated in billions worth of venture capital rounds, but GV is the industry's biggest spender.

The largest pharmas have a collective $188 billion in firepower to spend on M&A transactions, with all but one signaling a desire to execute, according to a new analysis from Leerink Partners.

Growth portfolio products like Leqembi and Spinraza helped drive Biogen to $2.8 billion in revenue for the third quarter.

Eli Lilly's next-gen weight loss drug retatrutide soundly beat Novo's approved medicine Ozempic in weight loss and blood sugar reduction, padding the case for a regulatory application that's expected in the first quarter of 2027.

Biogen is growing as planned, with marketed products generating more revenue and multiple late-stage readouts expected over the next year. Building out an early-stage pipeline would be a bonus, CEO Chris Viehbacher said on a Q3 earnings call Wednesday.

Eli Lilly's shares rose 4% in early morning trading after reporting revenue of $24.4 billion, well past consensus estimates.